Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.65 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.65 |
| ▸ | MCOLN1 | Q9GZU1 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27492507 | 0.88 | MCOLN2 (0.60) | POLBMEN1KMT2AHTTMCOLN2 | |
| SCHEMBL789616 | 0.88 | KEAP1 (0.72) | POLBMEN1KMT2AHTTLMNA | |
| SCHEMBL7571620 | 0.88 | POLB (0.68) | POLBMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL7572319 | 0.88 | POLB (0.68) | POLBMEN1KMT2AHTTMCOLN3 | |
| SCHEMBL2835167 | 0.87 | POLB (0.66) | POLBMEN1KMT2AHTTLMNA | |
| SCHEMBL7586724 | 0.87 | NPC1 (0.68) | POLBMEN1KMT2AHTTLMNA | |
| SCHEMBL2246137 | 0.87 | POLB (0.70) | POLBMEN1KMT2AHTTMAPT | |
| SCHEMBL8711266 | 0.86 | POLB (0.78) | POLBMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL1040233 | 0.84 | UQCRB (0.65) | POLBMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL7570459 | 0.84 | MEN1 (0.66) | POLBMEN1KMT2AHTTMCOLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | claimed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | claimed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | claimed |
| EP-0104353-B1 | HEAT SENSITIVE RECORD MATERIAL | HODOGAYA CHEMICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | claimed |
| US-4482905-A | FLUORAN, BENZENESULFONAMIDE, ACID, BINDER | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-11-13 | — | — | US | claimed |
| EP-0104353-A2 | Heat sensitive record material | HODOGAYA CHEMICAL CO., LTD. (JP) | 1984-04-04 | — | — | EP | claimed |
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | NAGOYA CITY UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | NAGOYA CITY UNIVERSITY (JP) | 2013-08-08 | — | — | US | disclosed |
| WO-2010005534-A2 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-2007760-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007108569-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIZIN-3-ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-09-27 | — | — | WO | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2002078970-A1 | HEAT SENSITIVE RECORDING MATERIAL | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
| EP-0610653-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5444036-A | Arylsulfonylureido compound, acetoacetanilide compound, sulfonamide derivative; storage stability | NEW OIL PAPER CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| EP-0610653-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203738-A1 | USE OF COMPOUND BINDING TO MSIN3B THAT SPECIFICALLY BINDS TO NEURON RESTRICTIVE SILENCER FACTOR (NRSF) | RCOR1, MSI2, RCOR3 | POLB 2035/4885MEN1 1167/4885KMT2A 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.